作者
Mark J Sarnak, Andrew S Levey, Anton C Schoolwerth, Josef Coresh, Bruce Culleton, L Lee Hamm, Peter A McCullough, Bertram L Kasiske, Ellie Kelepouris, Michael J Klag, Patrick Parfrey, Marc Pfeffer, Leopoldo Raij, David J Spinosa, Peter W Wilson
发表日期
2003/10/28
来源
Circulation
卷号
108
期号
17
页码范围
2154-2169
出版商
Lippincott Williams & Wilkins
简介
Chronic kidney disease1 (CKD) is a worldwide public health problem. In the United States, there is a rising incidence and prevalence of kidney failure, with poor outcomes and high cost. The number of individuals with kidney failure treated by dialysis and transplantation exceeded 320 000 in 1998 and is expected to surpass 650 000 by 2010. 1, 2 There is an even higher prevalence of earlier stages of CKD (Table 1). 1, 3 Kidney failure requiring treatment with dialysis or transplantation is the most visible outcome of CKD. However, cardiovascular disease (CVD) is also frequently associated with CKD, which is important because individuals with CKD are more likely to die of CVD than to develop kidney failure, 4 CVD in CKD is treatable and potentially preventable, and CKD appears to be a risk factor for CVD. In 1998, the National Kidney Foundation (NKF) Task Force on Cardiovascular Disease in Chronic Renal …
引用总数
20042005200620072008200920102011201220132014201520162017201820192020202120222023202472173206267286322354340354375343350384346289286249240230183102